Assessing developability early in the discovery process for novel biologics
Authors:
- Monica L. Fernández-QuinteroMFMonica L. Fernández-Quintero
- Anne LjungarsALAnne Ljungars
- Franz WaiblFWFranz Waibl
- Victor GreiffVGVictor Greiff
- Jan Terje AndersenJAJan Terje Andersen
- Torleif T. GjølbergTGTorleif T. Gjølberg
- Timothy P. JenkinsTimothy P. Jenkins
- Bjørn Gunnar VoldborgBVBjørn Gunnar Voldborg
- Lise Marie GravLGLise Marie Grav
- Sandeep KumarSKSandeep Kumar
- Guy GeorgesGGGuy Georges
- Hubert KettenbergerHKHubert Kettenberger
Top Cited Papers
Open Access
- 23 February 2023
- journal article
- review article
- Published by Taylor & Francis in mAbs
- Vol. 15 (1) , 2171248
Abstract
Beyond potency, a good developability profile is a key attribute of a biological drug. Selecting and screening for such attributes early in the drug development process can save resources and avoid costly late-stage failures. Here, we review some of the most important developability properties that can be assessed early on for biologics. These include the influence of the source of the biologic, its biophysical and pharmacokinetic properties, and how well it can be expressed recombinantly. We furthermore present in silico, in vitro, and in vivo methods and techniques that can be exploited at different stages of the discovery process to identify molecules with liabilities and thereby facilitate the selection of the most optimal drug leads. Finally, we reflect on the most relevant developability parameters for injectable versus orally delivered biologics and provide an outlook toward what general trends are expected to rise in the development of biologics.Keywords
Funding Information
- the European Research Council
- Horizon 2020
- UiO World-Leading Research Community
- Horizon 2020 (825821)
- Norwegian Cancer Society (215817)
- Horizon 2020
- Austrian Academy of Sciences
- Novo Nordisk Foundation (NNF20SA0066621)
- National Institutes of Health (RF1AG059723, R35GM136300)
- National Science Foundation (CBET1813963, CBET1605266, CBET1804313)
This publication has 235 references indexed in Scilit:
- Multivalent immune complexes divert FcRn to lysosomes by exclusion from recycling sorting tubulesMolecular Biology of the Cell, 2013
- Engineering neonatal Fc receptor-mediated recycling and transcytosis in recombinant proteins by short terminal peptide extensionsProceedings of the National Academy of Sciences, 2012
- General strategy for the generation of human antibody variable domains with increased aggregation resistanceProceedings of the National Academy of Sciences, 2012
- High-Throughput Analysis of Concentration-Dependent Antibody Self-AssociationBiophysical Journal, 2011
- Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potentialNature Communications, 2011
- Molecular dynamics simulations of protein dynamics and their relevance to drug discoveryCurrent Opinion in Pharmacology, 2010
- Cross-species Binding Analyses of Mouse and Human Neonatal Fc Receptor Show Dramatic Differences in Immunoglobulin G and Albumin BindingJournal of Biological Chemistry, 2010
- Analyses of the Recycling Receptor, FcRn, in Live Cells Reveal Novel Pathways for Lysosomal DeliveryTraffic, 2009
- Dynamic personalities of proteinsNature, 2007
- Phage antibodies: filamentous phage displaying antibody variable domainsNature, 1990